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Background: Statins have anti-inﬂ ammatory eﬀ ects in patients with chronic obstructive pulmonary disease (COPD). Th is study 
designed to evaluate the eﬀ ects of atorvastatin on serum highly sensitive C-reactive protein (hs-CRP) and pulmonary function in 
sulfur mustard exposed patients with COPD. Materials and Methods: Fifty patients with chronic obstructive pulmonary disease 
due to sulfur mustard and high serum hs-CRP entered in this study. Participants were randomized to receive 40 mg atorvastatin or 
placebo in a double-blind clinical trial. Forty-ﬁ ve patients completed the study (n = 23 atorvastatin and n = 22 placebo). Pulse oximetry 
(SpO2), pulmonary function test (PFT), and 6 min walk distance test (6MWD) was measured. COPD assessment test (CAT) and St. 
George’s respiratory questionnaire (SGRQ) were also completed by patients at the beginning of trial and after 9 weeks of prescription 
of 40 mg/day atorvastatin or placebo. At fourth week, SpO2, PFT, and 6MWD were again measured. After 9 weeks serum hs-CRP was 
re-measured. Results: Th ere was no signiﬁ cant diﬀ erence between atorvastatin and the placebo group in SpO2, FEV1, and 6MWD 
after fourth week (P = 0.79, P = 0.12, P = 0.12, respectively). Th e diﬀ erence between baseline and ninth week was calculated for two 
groups of trial and control in term of serum hs-CRP, SpO2, FEV1, and 6MWD. Signiﬁ cant improvement was not observed between 
two groups in above mentioned variables (P = 0.35, P = 0.28, P = 0.94, P = 0.43, respectively). However, the quality of life was improved 
by administration of atorvastatin using the CAT score (P < 0.001) and SGRQ total score (P = 0.004). Conclusion: Atorvastatin does 
not alter serum hs-CRP and lung functions but may improve quality of life in SM-injured patients with COPD.
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Interestingly, only 40% to 50% of SM exposed subjects 
seem to develop the pulmonary disease.[8] Chronic 
obstructive pulmonary disease (COPD) and Bronchiolitis 
obliterans (BO) are the main complications due to SM 
exposure. 
SM-exposed patients (SMP) suffer by an immune-
mediated airway disease associated with airway and 
systemic infl ammation. Previous studies have shown 
that circulating markers of systemic infl ammation, such 
as interleukin 6 (IL-6), C-reactive protein (CRP), and 
sputum eosinophilic cationic protein (ECP) are elevated 
in this patients.[9-11] CRP is an important component of 
the innate immune response, synthesized predominantly 
in the liver in response to IL-6, but it is also produced 
in the respiratory epithelium during infection.[12,13] 
Several studies have shown that high levels of CRP are 
associated with obstructive lung disease.[14] 
INTRODUCTION
Sulfur mustard (SM) as an alkylating agent was used 
against Iranian veterans by Iraq in the 1983-1988 Iraq–
Iran war. It is a vesicant chemical weapon, aﬀ ecting 
mainly the respiratory system, skin, and eyes with late 
complications. Long-term SM-induced complications 
have been reported in the intoxicated patients even 
16-20 years aĞ er exposure.[1]
The most common late complication of SM inhalation 
is respiratory tract injury. There are about 100,000 
surviving victims who were exposed to chemical 
warfare agents in Iran, many with permanent 
pulmonary disabil i t ies such as bronchiolit is 
obliterans.[2- 7]
The mechanism of effect of SM on respiratory tract 
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SMP oĞ en suﬀ er from symptoms such as dyspnea, cough, 
phlegm, chest tightness, exercise intolerance, and psychosocial 
abnormality. Common treatment and management guidance 
is largely based on the pulmonary function test (PFT) and 
forced expiratory volume in the fi rst second (FEV1). FEV1 
is weakly associated with various impact of disease on 
pulmonary and extra-pulmonary organs. 
Infl ammatory markers in SMP may increase susceptibility 
to exacerbation and mortality. Quality of life (QOL) is 
directly aﬀ ected by infl ammatory markers or there are some 
steps that can possibly play a role in this pathway? QOL 
improvement is an important goal in management of these 
patients. It has been postulated that the anti-infl ammatory 
eﬀ ects of statins may have relevance for the treatment of 
respiratory diseases.
Validated respiratory questionnaires such as COPD 
assessment test (CAT) and St. George’s respiratory 
questionnaire (SGRQ) are the preferred questionnaires for 
the assessment of QOL in these patients. 
In a previous study, high serum level of hs-CRP was found 
in patients injured with SM inhalation and respiratory 
complications.[9] Some investigators have shown that statins 
may be benefi cial in patients with ischemic heart disease 
and in COPD patients.[15,16]
Statins are inhibitors of 3-hydroxymethyl-3-glutaryl 
coenzyme A reductase (HMG CoA reductase); a rate-limiting 
step in cholesterol synthesis. In addition to cholesterol 
lowering properties, statins also have anti-infl ammatory 
eﬀ ects. Statin treatment therefore has the potential to modify 
immune-driven diseases.[17] Some investigators have shown 
that statins may be benefi cial in patients with ischemic heart 
disease and in COPD patients.[15,16]
However, relevant data in SMP with airfl ow limitation are 
lacking. It has been postulated that the anti-infl ammatory 
effects of statins may have benefit in the treatment of 
inflammatory airway disease such as SMP with late 
pulmonary complications. 
A recent trial of atorvastatin showed no improvement in 
controlling asthma but reduces sputum infl ammatory cells 
in atopic asthma.[17] Another study showed improvement 
in clinical outcome measures associated with reduction in 
blood infl ammatory biomarkers such as CRP and IL-6 in 
rheumatoid arthritis.[18] To the best of our knowledge, this 
study is the fi rst study that assessed the eﬀ ect of atorvastatin 
in the SMP in a double blind clinical trial.
The aim of this study was to evaluate eﬃ  cacy of adding 
atorvastatin to bronchodilator and corticosteroid inhalers 
on lung function improvement, airway inflammation 
indicators such as serum level of hs-CRP and QOL in SMP 
with obstructive pulmonary disease.
MATERIALS AND METHODS
We designed a randomized double-blind controlled trial 
to investigate the eﬀ ect of oral atorvastatin (40 mg daily 
for 9 weeks) on airway infl ammation (serum hs-CRP), 
saturation of hemoglobin with O2 by pulse oximetry (SpO2), 
PFT, 6 min walk distance (6MWD) test and QOL measured 
by CAT and SGRQ test in SMP with chronic obstructive 
pulmonary disease. Although the CAT is easy to use, SGRQ 
is time consuming and requires complicated spreadsheets to 
calculate the scores. The CAT questionnaire was translated 
to Persian and validated.[19]
Patients with obstructive pulmonary disease and 
documentation of SM exposure by military oﬃ  cials, the 
presence of respiratory complications, aged between 35 and 
85 years and elevated serum hs-CRP were recruited from 
hospital clinics in Ardabil during 11 months (4th February 
2011 to 6th December 2011). 
All subjects should not have a history of exacerbation during 
last 8 weeks prior to randomization and cigareĴ e smoking. 
Patients were encouraged to take their medications as usual 
stages of GOLD.
Patients were excluded from study in the case of chronic 
infl ammatory diseases, active liver and kidney diseases, 
cancer, cardiac diseases (MI and unstable angina in 
previous 6 months), current smokers, ex-smokers, opium 
addiction, receiving statins or having an allergic history 
to statins, active respiratory tract infection, bronchiectasis, 
myositis, myopathy, hypercholesterolemia, asthma, and 
elevated serum CPK. This study was approved by the ethics 
commiĴ ee of Ardabil University of Medical Sciences (Ref: 
902/6) and all participants signed an informed consent leĴ er.
FiĞ y males with confi rmed history of exposure to SM gas 
during the Iraq–Iran war who suﬀ ered from persistent 
respiratory complaints; shortness of breath and cough with 
chronic pulmonary airway obstruction and high serum 
level of hs-CRP accepted to participate. Subjects randomly 
(using an envelope containing allocated group) allocated 
in two groups of trial (oral atorvastatin 40 mg daily) and 
control (placebo) based on CONSORT fl ow diagram) [see 
Diagram 1]. Information on SpO2, PFT, 6MWD, serum 
hs-CRP, and quality of life were collected from subjects. Each 
treatment was administered for 9 weeks period. 
At the fi rst visit, age, respiratory symptoms, duration of 
symptoms, and drug history were asked. Meanwhile, 
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agglutinated particles produced in 552 nanometer lenge 
wave was measured by turbimetric assay. The normal range 
of hs-CRP was considered (0-5 mg/l), by this kit.
PFT
All participants underwent spirometry (HI-801 Chest 
Spirometer, Tokyo, Japan) at the fi rst visit, aĞ er 4 weeks of 
intervention and at the end of 9th weeks. The spirometer was 
calibrated using the device provided by the manufacturer. 
Forced expiratory volume in the fi rst second (FEV1), forced 
vital capacity (FVC), and FEV1/FVC ratio were measured 
to assess pulmonary function. 
SpO2 and 6 min walk distance test
O2 saturation of hemoglobin was measured by a pulse 
oximeter. Exercise capacity was done by 6MWD test 
between 8:00 a.m. and 14:00 p.m. 
Statistical analysis
the data were analyzed using SPSS soĞ ware version 16. 
Normally distributed data were expressed as mean and 
standard deviation (SD). Continuous variables were 
compared with the T-test and repeated measurement 
ANOVA. Bivariate correlations between diﬀ erent parameters 
were assessed using Pearson’s correlation coeﬃ  cients. A 
value of P < 0.05 was considered as statistically signifi cant. 
RESULTS
A total of 50 SMP with obstructive pulmonary disease 
from Ardabil university hospital clinics were invited 
to participate in the study. They were followed for 
height and weight, SpO2 and 6MWD were measured along 
with baseline lung function using a spirometer (HI-801 
Chest Spirometer, Tokyo, Japan). These respiratory tests 
(SpO2, PFT, and 6MWD) were repeated in week 4 and 9. In 
addition, patients were asked to fi ll CAT and SGRQ which 
were repeated aĞ er 9 weeks.
Three component scores of SGRQ are calculated: symptoms, 
activity, impacts, and a total score. Blood sample was drawn 
for hs-CRP assay at the end of ninth week. Symptoms that 
were considered potential adverse eﬀ ects of atorvastatin 
were acquired by self-administered questionnaire at second 
and third visits. 45 patients completed all three visits. Five 
patients did not complete the study due to incompliance 
to medicine (trial 2 and control 3). 
The primary outcome was serum hs-CRP. Secondary outcomes 
included SpO2, PFT, 6MWD, CAT, and SGRQ scores. Some 
researchers reported that 8 weeks of atorvastatin was long 
enough to show a clinical eﬀ ect, as serum cholesterol levels 
fall within 6 weeks of statin treatment. Therefore 9 weeks 
atorvastatin was chosen for trial period. Subjects were allocated 
in two groups of trial and control consequently.
Sulfur mustard exposure
Exposure to sulfur mustard was determined by 
documentation of military oﬃ  cials, pulmonary complication, 
and three pulmonologists documentation. 
Serum hs-CRP
Hs-CRP test was done by means of cobas Integra 400, 
using particle enhanced turbimetric assay method, the 
Diagram 1: Atorvastatin on mustard-gas-exposed patients study fl ow diagram
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9 weeks with 10% loss of follow-up. The patients were all 
male. There were not signifi cant diﬀ erences at baseline 
between two groups in demographic characteristics, 
anthropometrics and history of disease [Table 1]. There 
were not differences between two groups in terms 
of age, BMI, and hs-CRP at the beginning of study 
(P = 0.22, P = 0.33, P = 0.32, respectively).
There were no significant baseline hs-CRP differences 
between the placebo and trial groups. Atorvastatin did not 
reduce serum level of hs-CRP compared to placebo [Table 2]. 
Despite a signifi cant decrease in serum hs-CRP which was 
found within both groups of control and trial aĞ er study 
(P < 0.01 and P = 0.01, respectively) [Figure 1], a signifi cant 
diﬀ erence between two groups was not observed at 9th 
week. (Mean diﬀ erence = 2.93; 95% CI: -9.25 – 3.38) (P = 0.35)).
Table 3 demonstrates of FEV1, FEF 25–75%, SpO2, 6MWD, 
CAT score, and SGRQ total score in both groups at baseline 
and aĞ er 4 and 9 weeks. 
There was no significant difference in FEV1 between 
atorvastatin and placebo group in 9 weeks (P = 0.94) 
[Figure 2]. SpO2 and 6MWD test did not also improve by 
atorvastatin (P = 0.28 and P = 0.43, respectively). 
There was statically significant improvement with 
atorvastatin in quality of life with CAT score, and SGRQ 
total score compared with placebo (P < 0.001 and P = 0.004, 
respectively). 
It is found that severity of airflow limitation increase 
CAT and SGRQ total scores signifi cantly (P < 0.001 and 
P < 0.001, respectively). The SGRQ score and CAT scores 
show a positive linear correlation between two diﬀ erent tests 
assessing quality of life (P < 0.001, r = 0.97). Drug adverse 
event rates were similar in in two groups. Atorvastatin well 
tolerated by all patients none had any signifi cant subjective 
side eﬀ ects. 
Patients under atorvastatin had a beĴ er quality of life 
measured by CAT and SGRQ test compared to the control 
group [Figures 3 and 4].
DISCUSSION
In this study, we observed a signifi cant improvement on 
QOL measured with CAT and SGRQ by atorvastatin in the 
management of SMP with obstructive pulmonary disease 
while it was worse in placebo groups. On the other hand, 
despite QOL improvement in this study there were no 
statically diﬀ erence in hs-CRP and FEV1 between atorvastatin 
and placebo group. This suggests that perhaps these patients 
may benefi t from long-term treatment with atorvastatin. 
Although a signifi cant decrease of hs-CRP was observed, it 
is unclear and may happen due to seasonal variation. 
Previous studies have shown that statins may be benefi cial 
in patients with systemic infl ammation such as coronary 
artery disease and cause a signifi cant decrease in hs-CRP 
over the course of the study in COPD patients.[15] Study by 
Soyseth et al. showed mortality reduction with atorvastatin 
in COPD patients.[16] In some studies short-term treatment 
with atorvastatin does not alter lung function but improve 
quality of life in smokers with mild to moderate asthma.[20] 
Hothersall et al. reported a signifi cant reduction of sputum 
infl ammatory cells in asthma patients aĞ er the addition of 
Table 3: Parameters of subjects
Variable Baseline After 4 weeks After 9 weeks P value*
Baseline/after 9 weekControl group Trial group Control group Trial group Control group Trial group
FEV1 78.00±16.39 74.71±23.55 75.13±17.13 75.83±22.07 76.74±19.47 73.27±23.15 0.94
FEF 25-75% 76.91±40.68 71.70±34.90 74.46±36.73 75.94±40.43 69.88±34.67 74.47±35.68 0.66
SPO2 93.68±2.29 93.26±4.09 93.63±2.55 93.34±3.78 93.95±2.35 94.04±3.72 0.28
6MWD 372±132 366±149 363±141 372±141 365±139 369±148 0.43
CAT score 26.86±5.47 28.0±6.25 — — 27.45±5.60 24.78±6.73 <0.001
SGRQ score 64.37±17.83 67.50±19.53 — — 63.61±19.49 59.08±19.54 0.004
*: This shows signifi cance of differences between groups; FEV1 = Forced expiratory volume in the fi rst second; FEF 25-75% = Forced expiratory fl ow at 25-75% of the pulmonary 
volume; SPO2 = Saturation of hemoglobin with O2 by pulse-oximetry; 6MWD = Six minute walk distance; CAT = COPD assessment test; SGRQ = St. George’s respiratory 
questionnaire
Table 1: Distribution of basic information in two groups
Variable Control 
group N = 22
Trial 
Group N = 23
P value




BMI (kg/m2) 30.02±4.53 28.71±4.48 0.33
*All subjects were male; BMI = Body mass index
Table 2: Distribution of hs-CRP levels at baseline and 
week 9
Serum hs-CRP mg/L Control group Trial group P Value
At baseline 13.60±11.40 10.70±7.30 0.35*
End of study 6.04±4.06 6.10±3.69
P value within group <0.01 0.01
*: This show between group’s differences is not signifi cant; hs-CRP = Highly sensitive; 
C-Reactive protein 
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atorvastatin to inhaled corticosteroids but did not improve 
asthma control in short term.[17] 
Study by Ghanei et al. found a signifi cant improvement of 
severity of pulmonary symptoms and ventilator parameters 
after 4 months treatment with N-acetyl cysteine, their 
conclude that the benefi cial eﬀ ect of N-acetyl cysteine may 
be mediated by its antioxidative properties.[21] 
Some studies suggest that tissue remodeling is involved in 
SM-exposed lung damage patients.[22] Numerous studies 
have revealed that this disorder is strongly associated with 
systemic infl ammation and oxidative stress and decreased 
levels of endogenous antioxidants.[23-25]
Several mechanisms, either alone or together, might explain 
these fi nding. Firstly, statins may improve cardiovascular 
function; it is likely that some of the SMP had unrecognized 
IHD. Secondly, the lower score of CAT and SGRQ in patients 
treated with atorvastatin may be due to extra-pulmonary 
eﬀ ect of statins and fi nally, statins may decrease the sputum 
infl ammatory cells, and may reduce release of cytokines 
and infl ammatory marker other than hs-CRP including IL-6 
and TNFa from monocytes and endothelial cells.[17] Thus, 
the benefi cial eﬀ ect of atorvastatin may be mediated by an 
anti-infl ammatory eﬀ ect in the airway.
Pathophysiology of SM respiratory complication has 
not been clearly understood but these complications are 
induced by airway disease with systemic infl ammation. SM 
can cause chronic injuries to a wide range of physiological 
systems. In particular, complications occur on the 
respiratory tract, skin, eyes, and immune system.[26] 
Our study demonstrated that airway obstruction and 
ventilator parameters did not improved after 9 weeks 
administration of 40 mg atorvastatin. Atorvastatin is widely 
used as anti-infl ammatory agents in cardiovascular and 
pulmonary disease (especially in COPD) does not show 
a signifi cant benefi t in pulmonary function in obstructive 
pulmonary complication due to sulfur mustard gas. 
Lee et al. reported exercise capacity improvement and serum 
hs-CRP reduction with statins aĞ er 6 months intervention in 
COPD patients.[15] However, the fi nding of our study did not 
support this result. In this study, we did not fi nd signifi cantly 
improvement of FEV1 by atorvastatin in SMP. The possible 
reason for lack of association is that SMP-like subjects with 
Figure 1: Serum hs-CRP within both groups of control and trial at beginning 
and after study
Figure 2: FEV1 in both groups of control and trial at baseline and 9th week
Figure 3: CAT score in control and trial groups at baseline and 9th week Figure 4: SGRQ total score in control and trial groups at baseline and 9th week
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COPD have a persistent and irreversible airfl ow limitation 
as was suggested by previous studies. Therefore, it can 
be assumed that FEV1 and PFT are not a reliable test for 
evaluating multiple consequences of systemic infl ammation 
in pulmonary diseases.[27,28] Although PFT is a valuable 
diagnostic instrument for evaluation of severity of airfl ow 
obstruction this test cannot be used for evaluation of 
treatment eﬃ  cacy on extra-pulmonary consequence of SM 
injured patients during regular follow-up. 
Some investigators have reported a signifi cant association 
between CAT and disease severity obtained by lung 
function in SMP with airfl ow obstruction.[29] The CAT and 
SGRQ were designed to measure QOL in COPD patients in 
clinical practice. These tests were used in SMP with airfl ow 
limitation. We observed that both CAT and SGRQ exhibit 
signifi cant correlation with airfl ow limitation and can be 
used as a reliable tools to assess quality of life in SMP. The 
agreement between the two questionnaire scores is high. 
CAT is simple, shorter, and easily can be used compared 
to SGRQ. Patients with severe airfl ow limitation reported 
worse quality of life, measured with both CAT and SGRQ 
similarly to other studies in COPD patients.[30]
In addition, we noticed that atorvastatin do not have 
benefi cial eﬀ ect on SM patients exercise capacity measured 
by 6MWD test and SpO2. 
This study has some limitations. First, the time of intervention 
and follow-up was not long, that may alter the study fi nding. 
Second, the serum level of other infl ammatory markers such 
as IL-6 and TNFa has not been measured. Third, treatment 
with inhalation corticosteroids and bronchodilator may 
have aﬀ ected atorvastatin metabolism. Fourth, all subjects 
were male. And fi nally the sample size was relatively small. 
Therefore, a complementary study with large sample size 
and long-term intervention with atorvastatin is appreciated.
CONCLUSION
In conclusion, we have shown that atorvastatin in SMP who 
suﬀ ered from chronic respiratory complications did not 
alter serum hs-CRP, PFT, and 6MWD and did not increase 
SpO2 at air room but associated with QOL improvement 
using CAT and SGRQ. 
In summary, improvement in QOL suggests that atorvastatin 
could be used in addition to the conventional therapies in 
these patients.
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